Weekly Investment Analysts’ Ratings Updates for Amgen (AMGN)

Amgen (NASDAQ: AMGN) recently received a number of ratings updates from brokerages and research firms:

• 6/27/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/18/2026 – Amgen had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 6/18/2026 – Amgen had its “positive” rating reaffirmed by Royal Bank Of Canada.
• 6/16/2026 – Amgen had its price target raised by Mizuho from $295.00 to $303.00. They now have a “neutral” rating on the stock.
• 6/14/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/12/2026 – Amgen had its “overweight” rating reaffirmed by Piper Sandler.
• 6/9/2026 – Amgen had its price target raised by Morgan Stanley from $332.00 to $340.00. They now have an “equal weight” rating on the stock.
• 6/6/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/5/2026 – Amgen was given a new $389.00 price target by The Goldman Sachs Group, Inc..
• 5/23/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/20/2026 – Amgen had its price target lowered by Argus from $400.00 to $375.00. They now have a “buy” rating on the stock.
• 5/14/2026 – Amgen had its price target lowered by Piper Sandler from $432.00 to $427.00. They now have an “overweight” rating on the stock.
• 5/13/2026 – Amgen had its price target lowered by Daiwa Securities Group Inc. from $410.00 to $390.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Amgen was upgraded by Freedom Capital from “hold” to “strong-buy”.
• 5/5/2026 – Amgen had its “hold” rating reaffirmed by Erste Group Bank AG.
• 5/4/2026 – Amgen had its price target lowered by Guggenheim from $351.00 to $340.00. They now have a “neutral” rating on the stock.
• 5/1/2026 – Amgen was given a new $332.00 price target by Morgan Stanley.
• 5/1/2026 – Amgen had its price target raised by Truist Financial Corporation from $325.00 to $327.00. They now have a “hold” rating on the stock.
• 5/1/2026 – Amgen had its price target raised by The Goldman Sachs Group, Inc. from $415.00 to $425.00. They now have a “buy” rating on the stock.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.